Pacific Edge taps investors for cash again
The US market is proving a hard nut to crack for the cancer diagnostics firm
Tim Hunter
Thu, 29 Nov 2018
Cancer diagnostics company Pacific Edge is going back to shareholders for more capital as it continues to burn through cash in its quest for a US breakthrough.
After its shares were placed in a trading halt today Pacific Edge announced a share placement to raise $7 million at 35c a share,
Want to read more? It's easy.
Choose your subscription
Already have an account? Login
Smartphone Only Subscription
NZ$29.95 / monthly
Subscribe Now
Monthly Premium Online Subscription
NZ$49.95 / monthly
Subscribe Now
Smartphone Only Annual Subscription
NZ$299.00 / yearly
Subscribe Now
Yearly Premium Online Subscription
NZ$499.00 / yearly
Subscribe Now
Premium Group Membership 10 Users
NZ$385+GST / monthly
$38.5 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 20 Users
NZ$660+GST / monthly
$33 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 50 Users
NZ$1375+GST / monthly
$27.5 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 100 Users
NZ$2100+GST / monthly
$21 per user - Pay by monthly
credit card debit
Subscribe Now
Yearly Premium Online Subscription + NBR Marketplace
NZ$999.00 / yearly
Subscribe Now
Individual
Group membership
NBR Marketplace
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
Tim Hunter
Thu, 29 Nov 2018
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
